SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022SARS-CoV-2 Omicron 변이체 BA.2 중화, Comirnaty 또는 CoronaVac 백신 접종, 감염 또는 돌발성 감염, 홍콩, 2020년에서 2022년까지Article Published on 2022-05-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] affecting antibody Beta BNT162b2 Breakthrough infection breakthrough infections circulation comparable CoronaVac Delta detectable dose elicited evaluated followed by help Hong Kong hybrid-immunity individual individuals Infection neutralisation neutralisation test neutralisation tests Neutralising Antibodies neutralising antibody neutralising antibody response neutralising antibody titre neutralising antibody titres neutralization omicron other variant other variants PRNT reduction response SARS-CoV-2 SARS-COV-2 infection sera significantly single vaccine subvariant BA.1 subvariant BA.2 symptomatic infection titre titres uninfected vaccination Vaccine vaccinee vaccinees variant viruses wild type [DOI] 10.2807/1560-7917.ES.2022.27.18.2200178 PMC 바로가기 [Article Type] Article
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021유럽에서 델타 순환이 우세한 동안 1차 진료 및 지역사회 수준에서 COVID-19에 대한 완전한 1차 백신 접종의 효과: 다중 센터 분석, I-MOVE-COVID-19 및 ECDC 네트워크, 2021년 7월~8월Multicenter Study Published on 2022-05-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory symptom acute respiratory symptoms Analysis circulation Community Complete Course COVID-19 COVID-19 vaccine Delta delta variant ECDC Effectiveness Europe European country janssen multicentre multicentre study Older predominant primary care Sample size SARS-CoV-2 symptomatic symptomatic infection test-negative design tested the SARS-CoV-2 the vaccine vaccination vaccination against COVID-19 Vaccine vaccine effectiveness while with COVID-19 [DOI] 10.2807/1560-7917.ES.2022.27.21.2101104 PMC 바로가기 [Article Type] Multicenter Study
Diagnostic Value of a SARS-CoV-2 Rapid Test Kit for Detection of Neutralizing Antibodies as a Point-of-Care Surveillance Test현장 감시 검사로서 중화 항체 검출을 위한 SARS-CoV-2 신속 검사 키트의 진단 가치Article Published on 2022-04-272022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition antibody Antibody test antibody tests Antibody titer Antibody titers assays caused Characteristics Cohort Concentration convalescence coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 symptoms cross-reactivity defined demonstrated detect detection diagnostic diagnostic test diagnostic tests display epidemiological evaluate evaluated Health Organization humoral Humoral response IgG and IgM IgG antibodies IgG test IgM antibodies immune protection immunization implementation increasingly individual Infection intensity international standard Interpretation limit of detection Live virus microneutralization NAb NAb titers NAbs Neutralizing antibodies neutralizing antibody observé pandemic point-of-care population surveillance Predictive profiles public health measure public health measures Rapid Rapid diagnostic test Rapid tests RDT RDTs recovered COVID-19 patient reducing mortality respiratory reveal SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody sensitivity Serological assay Seropositivity severe acute respiratory syndrome Coronavirus specificity Standard Surveillance symptomatic infection Test test line the SARS-CoV-2 the WHO Transmission Vaccinations value was determined while WHO World Health Organization [DOI] 10.1128/spectrum.00993-21 PMC 바로가기 [Article Type] Article
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era백신 시대 동안 캐나다 헌혈자의 SARS-CoV-2 혈청 유병률 패턴 변화Article Published on 2022-04-272022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age anti-S antibody Antibody concentrations Asymptomatic benefit Blood blood donor Blood donors Canada capita Changing Concentration coronavirus country Donor donors estimate expand full length group groups Health Organizations Health policy Humoral immunity identify Interaction mathematical Mathematical models National natural infection nucleic acid nucleocapsid Older organization pandemic pattern peaked positive Predictive proportion public health remained respiratory roll SARS-CoV-2 SARS-CoV-2 nucleic acid SARS-CoV-2 spike second dose Seroprevalence severe acute respiratory syndrome Coronavirus Spike protein symptomatic infection These data vaccination Vaccine [DOI] 10.1128/spectrum.00339-22 PMC 바로가기 [Article Type] Article
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염 및 B.1.1.7 항체 및 백신 접종 상태에 따른 의료 종사자의 변이 감염 발생률에 대한 관찰 코호트 연구Observational Study Published on 2022-04-092022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age anti-spike antibodies anti-spike antibody antibody B.1.1.7 B.1.1.7 variant BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Chain Reaction changes in confidence interval coronavirus coronavirus 2 detectable dose doses evade Evidence evidence of HCW HCWs healthcare healthcare worker Healthcare workers Immunity incidence incidence rate Infection investigated longitudinal cohort study natural natural immunity natural infection no evidence of Oxford-AstraZeneca pandemic PCR-positive Pfizer-BioNTech Poisson regression polymerase chain polymerase chain reaction provided rate ratio reduced respiratory resulting robust S-gene SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants Sequencing seronegative seropositive Seropositivity severe acute respiratory syndrome Coronavirus Sex Single-dose status symptomatic symptomatic and asymptomatic symptomatic infection United Kingdom vaccination Vaccine vaccine dose Vaccine-induced immunity whole genome Whole genome sequencing without symptom worker [DOI] 10.1093/cid/ciab608 PMC 바로가기 [Article Type] Observational Study
CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 testCHARM: qPCR SARS-CoV-2 테스트 양성 후 무증상 및 증상 감염에 대한 항원 특이적 인터페론-감마 및 IL2 반응의 해병을 위한 COVID-19 건강 조치 대응Article Published on 2022-04-072022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] Action All participants Asymptomatic Asymptomatic cases Cell mediated immunity class correlated COVID-19 COVID-19 symptoms COVID-19 vaccine COVID-19 vaccines dropped enrolled Enrollment epitope Epitopes Follow-up frequencies Frequency IFN-γ IFN-γ response IFN-γ responses IL2 immune response include Infection membrane N and M N and S proteins N protein nucleocapsid occurred participant Participants peaked peptide peptide pool peptides positive Post-infection predicted Protein Proteins qPCR qPCR test Responder response responses S proteins S, N and M proteins SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 test significantly Study participants subjects Support symptomatic symptomatic and asymptomatic symptomatic infection symptomatic participants T cell T cell response T cell responses tested the N protein These data were measured with COVID-19 [DOI] 10.1371/journal.pone.0266691 PMC 바로가기 [Article Type] Article
Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees독일 대학생 및 직원의 COVID-19 백신 부스터 주저의 확산 및 동인Article Published on 2022-04-072022-09-11 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI addition addressed adjusted odds ratio Administered age anamnesis BNT162b2 booster Community community health community transmission conducted confidence interval COVID-19 COVID-19 vaccine COVID-19 vaccines cross-sectional Cross-sectional studies cross-sectional survey Decision making demographic characteristics determinant dose doses Effectiveness employee evaluate family health females Germany Health health protection Hesitancy Hospitalized Immunity Infection less majority over pandemic participant Patient predictor prevalence of COVID-19 primer promoters public health questionnaire receive receiving recruited social determinant social determinants social determinants of health student subset symptomatic infection university vaccination Vaccination hesitancy Vaccine vaccine dose variant viral variant [DOI] 10.3389/fpubh.2022.846861 PMC 바로가기 [Article Type] Article
Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study중국 광둥성 발병 기간 동안 B.1.617.2(델타) 변종으로 인한 질병에 대한 비활성화된 COVID-19 백신의 효과 : 코호트 연구Observational Study Published on 2022-04-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adjusted Against age Analysis B.1.617.2 China cohort study COVID-19 COVID-19 vaccine Critical Critical illness Delta development dose doses effective Effectiveness effort Evidence foundation Guangdong illness immunization inactivated Inactivated vaccine Inactivated Vaccines Infection infections laboratory-confirmed natural observational study outbreak outcome participant Participants Patient Pneumonia populations Primary outcome Program reported research and development Result retrospective cohort study Science secondary outcome Secondary outcomes severe or critical illness severity symptomatic infection symptomatic infections vaccination Vaccine variant variant of SARS-CoV-2 [DOI] 10.7326/M21-3509 PMC 바로가기 [Article Type] Observational Study
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022오미크론 및 델타 증상 감염 및 심각한 COVID-19 결과에 대한 백신 유도 및 자연 획득 보호, 프랑스, 2021년 12월 ~ 2022년 1월Article Published on 2022-04-012022-09-11 Journal: Eurosurveillance [Category] COVID19(2023년), SARS, 변종, [키워드] Delta Effectiveness epidemic wave France Immunity omicron outcome outcomes protection provided SARS-CoV-2 severe COVID-19 symptomatic individuals symptomatic infection Test Test negative design vaccination vaccination effectiveness variant waned [DOI] 10.2807/1560-7917.ES.2022.27.16.2200250 PMC 바로가기 [Article Type] Article
Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 InfectionSARS-CoV-2 후 재감염 위험: SARS-CoV-2 감염 후 면역을 부여하는 데 있어 항체 반응의 역할에 대한 미국 의과대학 실습 요점을 위한 살아있는 신속한 검토Review Published on 2022-04-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI Alpha variant Asymptomatic Care Clinical practice college database Delta diagnose eligible Evidence General population Health care Health care worker health care workers Health Organization Immunity Immunocompromised index case individual individuals Infection infection risk infection with SARS-CoV-2 investigator Longitudinal studies longitudinal study Meta-analysis omicron OVID Patient physician Point Practice prevented PROSPERO protection public health Quality Racial ranged Rapid reduced risk Reinfection remained response Result review risk risk difference role SARS-CoV-2 SARS-COV-2 infection strength subgroups symptomatic symptomatic infection symptomatic infections uninfected variant variants wild-type World Health Organization [DOI] 10.7326/M21-4245 PMC 바로가기 [Article Type] Review